Director Christopher D. Payne filed a Form 4 with the SEC on August 14, 2026, disclosing the acquisition of two tranches of Restricted Stock Units in Hims & Hers Health, Inc. (NASDAQ:HIMS) on August 12, 2026.

Key Highlights

  • RSU grant - tranche 1: Payne was awarded 8,223 Restricted Stock Units in Class A Common Stock on August 12, 2026, at a price of $0.
  • RSU grant - tranche 2: A second grant of 545 RSUs was issued on the same date, also at a price of $0, in lieu of the director retainer fee for Q2 2026.
  • Retainer fee conversion: The 545-unit grant was calculated by dividing foregone cash fees of $16,598 by a grant price of $30.40, per the company's Director Compensation Policy.
  • Total RSUs held: Following both transactions, Payne directly holds 8,223 RSUs from the first tranche and 545 RSUs from the second tranche.
  • Vesting schedule: The 8,223-unit tranche vests in full on the first company quarterly vesting date after the earlier of the next annual stockholder meeting or the first anniversary of the grant date; the 545-unit tranche vests on the company's next quarterly vesting date.
  • Reporting person role: Payne is identified as a Director of Hims & Hers Health, Inc.

Christopher D. Payne RSU Awards: Transaction Details and Vesting Terms

According to the filing, Christopher D. Payne received two separate Restricted Stock Unit grants from Hims & Hers Health, Inc. on August 12, 2026, both recorded under transaction code "A" (acquired). Each RSU represents a contingent right to receive one share of Class A Common Stock, and both grants were recorded at a derivative security price of $0.

The first grant, totaling 8,223 RSUs, is subject to continuous service and will vest in full on the first company quarterly vesting date following the earlier of the company's next annual stockholder meeting or the first anniversary of the grant date, as described in the filing's explanations. The second grant, totaling 545 RSUs, was issued pursuant to the issuer's Director Compensation Policy as a substitute for Payne's cash director retainer fee for the second quarter of 2026. The filing states that the number of units was determined by dividing the foregone cash fees of $16,598 by the grant price of $30.40. This tranche will vest in full on the company's next quarterly vesting date.

Both grants are held directly by Payne. The Form 4 was signed on August 14, 2026, by Kimberly Mather as attorney-in-fact for Christopher D. Payne. No disposition of securities was reported in this filing.

What Was Disclosed

The filing discloses two RSU awards to director Christopher D. Payne in Hims & Hers Health Class A Common Stock, totaling 8,768 units combined, granted on August 12, 2026, one of which replaced a Q2 2026 cash retainer fee of $16,598.